Clinical Strategies in the Management of Biochemical Recurrence after Radical Prostatectomy

Clinical Prostate Cancer

Volumn 2, Issue 3, 2003, Pages 160-166

  Zimmerman, Robert A ^a   Culkin, Daniel J ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen deprivation; Hormonal therapy; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; NILUTAMIDE; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ALGORITHM; ANEMIA; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CRYOSURGERY; EDEMA; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HORMONAL REGULATION; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; LYMPH NODE METASTASIS; MASTALGIA; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0347595572     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.024     Document Type: Review

References (57)

1. Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Wingo PA, Guest JL, McGinnis L, et al. Patterns of inpatient surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988-1995. Cancer Causes Control 2000; 11:497-512.
3. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166:416-419.
4. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996; 14:2258-2265.
5. Carroll P. Rising PSA after a radical treatment. Eur Urol 2001; 40(suppl)2:9-16.
6. Narain V, Tiguert R, Banerjee M, et al. Biochemical recurrence after radical prostarectomy in black and white American men with a positive or negative family history of prostate cancer. J Urol 2001; 165:474-477.
7. Grossfeld GD, Li YP, Lubeck DP, et al. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2002; 168:530-535.
8. Fowler FJ, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993; 42:622-629.
9. Lu-Yao GL, Potosky AL, Albertsen PC, et al. Follow-up prostate cancer treatments after radical prostatectomy: a population based study. J Natl Cancer Inst 1996; 88:166-173.
10. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 1998; 160:1398-1404.
11. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 1988; 139:766-772.
12. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins Experience after 10 years. Urol Clin N Am 1993; 20:713-725.
13. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994; 74:104-114.
14. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166:1322-1327.
15. Grossfeld GD, Tigrani VS, Nudell D, et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 2000; 164:93-100.
16. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 28:11591-1597.
17. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165:1146-1151.
18. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152:1837-1842.
19. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting recurrence after radical prostatectomy for patients with high-risk prostate cancer. J Urol 2003; 169:157-163.
20. Sofer M, Savoie M, Kim SS, et al. Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 2003; 169:153-156.
21. Partin AW, Yoo J, Carter HB, et al. The use prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men localized prostate cancer. J Urol 1993; 150:110-114.
22. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy. J Urol 1995; 154:131-138.
23. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate. J Natl Cancer Inst 1998; 90:766-771.
24. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58:843-848.
25. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517-523.
26. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk cancer patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13:111-116.
27. Theodorescu D, Lippert MC, Broder SR, et al. Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision. Urology 1998; 51:277-282.
28. Roberts WW, Bergstralh EJ, Blute ML, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57:1033-1037.
29. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-1445.
30. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649-659.
31. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152:1821-1825.
32. Cher ML, Bianco FJ Jr, Lam JS, et al. Limited role of bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160:1387-1391.
33. Kramer S, Gorich J, Gottfried HW, et al. Sensitivity of computer tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997; 70:995-999.
34. Connolly JA, Shinohara K, Presti JC Jr, et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate specific antigen and surgical margins. Urology 1996; 47:225-231.
35. Kahn D, Williams RD, Haseman MK, et al. Radioimmunoscintigraphy with In-III labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16:284-289.
36. Lee RW, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 1996; 156:450-453.
37. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52:154-179.
38. Carroll PR, Kantoff PW, Balk SP, et al. Overview consensus statement. Urology 2002; 60(3 suppl 1):1-6.
39. Blackard CE, Byar DP, Jordan WP Jr. Orchiectomy for advanced prostatic carcinoma: a re-evaluation. Urology 1973; 1:553-560.
40. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19:3750-3757.
41. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337:295-300.
42. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341:1781-1788.
43. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001; 87:47-56.
44. Anderson JB. Early versus deferred hormone therapy. Eur Urol 1999; 36(suppl 2):9-13.
45. Casselith BP, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1992; 1:323-329.
46. Klotz LH, Herr HW, Morse MJ, et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58:2546-2550.
47. Wolf JM, Tunn UW. Intermittent androgen blockade in prostate cancer: rational and clinical experience. Eur Urol 2000; 38:365-361.
48. Bruchovsky N, Klotz LH, Sadar M, et al. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol 2000; 4:191-199.
49. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51:137-144.
50. Dawson NA. Intermittent androgen deprivation. Curr Oncol Rep 2000; 2:409-416.
51. Chodak G, Sharifi R, Kasimis B, et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46:849-855.
52. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424.
53. Boccardo F, Pace M, Robagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29:1088-1093.
54. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036-1042.
55. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355:1491-1498.
56. Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168:542-545.
57. Oh WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002; 60(3 suppl 1):87-92.